Somewhere...in the dark corners of the internet and on Wall St. there lurks a person or entity that is in total control of this stock. And....they're very good at what they do.
What's going to wrest control away from them ?? Big institutional money pouring in from all sides.
What's going to attract big institutional money ? Earnings, royalties, cash, maybe some partnerships.
We've got a chance with partnerships....and maybe we get a few of those this year.
The rest of those things will come....but, it might be years. Mage3 would have been nice......Butkus.
Better numbers from HepV would have been nice....semi-Butkus.
What to do ?? Try to guess the bottoms and then sell on blips.
to a similar small speculative company, AcelRx, ACRX, has just about the same cash pile as AGEN, it's about 40M shares versus about 64M shares in AGEN. ACRX EPS is (0.22) while AGEN is losing half that at about (0.12) and falling rapidly. ACRX has a few things going for it but not the multitude that AGEN has.
The kicker is that ACRX is trading over $11/share!!!! AGEN still trading down just above $3!!!!
Analyzing the differences and balance sheet and earnings / cost figures and taking into consideration what each brings to the table for shareholders, it does not appear that ACRX intrinsically has over three times the value of AGEN. It just does not make sense.
Why is AGEN not trading over $10/share?!
Does anyone get it? Please explain, TIA.
Sentiment: Strong Buy
"..I think we have a best in class platform for generating optimized antibodies that have not only the right pharmacologic properties but the right pharmaceutical properties which it will help them speed through development eventual commercialization. Two, we have the full spectrum of the six most important targets at this point and it’s going to be much more doable for us to combine them in different ways than it will be for many of the competitors that are in the full space. Three, we didn’t have the opportunity to use on top of our new education strategies and this is clearly turning out to be important. The big thrilling news at [indiscernible] is that when combined check point together you get really amazing efficacy we also get pretty scary side effects and learning to aim the immune response so that you can get to the same level attack on the tumor without as much attack on normal tissue is going to become increasingly recognizes important and I think that there is the beginning of the ground stalled interest again in cancer vaccines which will allow that immune education to turn more effectively. "
Dr.Stein at the CC said:
"our work advances with our six-preclinical CPM programs on schedule towards IND filing in 2015 to 2016 there are well over 50 additional checkpoint related proteins to explore and exploit still. Our Retrocyte Display platform will be applied to additional checkpoint related targets to enhance our portfolio."
Sentiment: Strong Buy
"all agen really gets is a little bit of bragging rights because it doesn't work that well...."
Dear STP Corporation,
Your product doesn't work that well.
I put it in my car which has a cracked engine block, and while it did cause the DMV to deem it now to be road worthy, I am disappointed because it only raised my MPG by 25%.
Hillbilly Addative Basher
all agen really gets is a little bit of bragging rights because it doesn't work that well, and there is no profit to speak of in it
to many failures are working against agen at this point
doesn't matter how many irons are in the fire if the fire has gone out
not to mention that the shorts are already doing well with this stock, and they know that even in the slim chance agen's adjuvant finds its way into a product it is not going to get much for it
The 33% jump in S/I is troublesome, as those guys seem to never be wrong about AGEN.
They apparently know there's somethin' out there.....hiding in the tall grass.
It DID go higher on the "news"....then the old adage "sell the news" kicked in.
I still think AGEN is under accumulation, however.
Shorts have increased significantly this month. Some see the historic price chart and assume that this stock will always make spikes and then drop back down immediately, so they go short trying to capture the opportunity to short it high and ride it down and cover low making profits. However, this has worked in the past but it will not necessarily work in the future, it will work until it doesn't and at that time the shorts will lose all their profits and likely most of their capital as they cover in an environment where share supply is scarce because of major news and with a sky rocketing price they will be forced to pay up big time to cover. Worst case scenario for the shorts is one morning before the bell we see news that AGEN was bought out by big pharma bio tech for 2X, 3X ... nX the current share price. That is the risk the shorts take, but they suppose they can handle it so long as they can control the volume and price on low volume days. Today so far down 5.5% on 200,000 shares traded, most of which were probably phony wash trades back and forth between their own internal accounts, meanwhile the day prior 2M trade pushing PPS over 11%. It's all a mirage, the short sellers prey on any type of company which is losing money every quarter and must dilute to keep the lights on, its shorting 101. Then they can always bash and blame the CEO (failures, etc) for the stock declines, when really it's them systematically pushing the PPS down down down every day with 100 share lots at a time. Whenever the institutions decide to accumulate more, they will swat the flies away with a wave of their hand and the crony shorts will scatter like roaches from the scene. All of these PPS fluctuations are FAKE, ignore them, the current price is manipulated and means nothing, they know it, institutions know it and big pharma knows it, you should too.
Sentiment: Strong Buy
In a research report issued this morning, H.C. Wainwright analyst Reni Benjamin reiterated coverage with a Buy rating on Agenus Inc. (AGEN), and a $6 price target, following AGEN’s second quarter update.